1H NMR metabolomic signatures in five brain regions of the aβPPswe Tg2576 mouse model of Alzheimer's disease at four ages

Journal of Alzheimer's Disease

Volumn 39, Issue 1, 2014, Pages 121-143

  Lalande, Julie ^a   Halley, Hélène ^a   Balayssac, Stéphane ^a   Gilard, Véronique ^a   Déjean, Sébastien ^a   Martino, Robert ^a   Francés, Bernard ^a   Lassalle, Jean Michel ^a   Malet Martino, Myriam ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Alzheimer's disease; A PPswe Tg2576 mouse model; biomarkers; metabolomics

Indexed keywords

4 AMINOBUTYRIC ACID; CREATINE; GLUTAMIC ACID; INOSITOL; N ACETYLASPARTIC ACID; PHOSPHORYLCHOLINE; TAURINE; AMYLOID PRECURSOR PROTEIN; ASPARTIC ACID; BIOLOGICAL MARKER; DRUG DERIVATIVE; N-ACETYLASPARTATE; TISSUE EXTRACT;

ADULT; AGE; AGE DISTRIBUTION; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CEREBELLUM; COGNITIVE DEFECT; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; MALE; MESENCEPHALON; METABOLOMICS; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RHINAL CORTEX; TG2576 MOUSE; TRANSGENIC MOUSE; WILD TYPE; $^1$H NMR; AGING; ANIMAL; AΒPPSWE TG2576 MOUSE MODEL; BRAIN CORTEX; DISEASE MODEL; GENOTYPE; METABOLISM; METABOLOME; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY;

$^1$H NMR; ALZHEIMER'S DISEASE; AΒPPSWE TG2576 MOUSE MODEL; BIOMARKERS; METABOLOMICS;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASPARTIC ACID; BIOLOGICAL MARKERS; CEREBELLUM; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; GENOTYPE; GLUTAMIC ACID; HIPPOCAMPUS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MESENCEPHALON; METABOLOME; MICE; MICE, TRANSGENIC; TISSUE EXTRACTS;

EID: 84892779084     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130023     Document Type: Article

References (70)

1. Schmechel DE, Goldgaber D, Burkhart DS, Gilbert JR, Gajdusek DC, Roses AD (1988) Cellular localization of messenger RNA encoding amyloid-beta-protein in normal tissue and in alzheimer disease. Alzheimer Dis Assoc Disord 2, 96-111.
2. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 4913-4917.
3. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639. (Pubitemid 39061671)
4. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
5. Dickson DW (1997) Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopathological studies. Neurobiol Aging 18, S21-S26. (Pubitemid 27454692)
6. Braak H, Braak E (1998) Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 53, 127-140. (Pubitemid 28361774)
7. Jiang N, Yan X, ZhouW, Zhang Q, Chen H, Zhang Y, Zhang X (2008) NMR-based metabonomic investigations into the metabolic profile of the senescence-accelerated mouse. J Proteome Res 7, 3678-3686.
8. Oresic M, Hÿotyl̈ainen T, Herukka SK, Sysi-Aho M, Mattila I, Sepp̈anan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, L̈otj̈onen J, Soininen H (2011) Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1, e57.
9. Ibáñez C, Simó C, Mart́n-Á lvarez PJ, Kivipelto M, Winblad B, Cedazo-Ḿnguez A, Cifuentes A (2012) Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal Chem 84, 8532-8540.
10. Oberg J, Spenger C, Wang FH, Andersson A, Westman E, Skoglund P, Sunnemark D, Norinder U, Klason T, Wahlund LO, LindbergM(2008) Age related changes in brain metabolites observed by 1HMRS in APP/PS1 mice. Neurobiol Aging 29, 1423-1433. (Pubitemid 351970599)
11. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, McGowan E, Emson PC, Griffin JL (2010) A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 56, 937-947.
12. Trushina E, Nemutlu E, Zhang S, ChristensenT,CampJ, Mesa J, Siddiqui A, Tamura Y, Sesaki H, Wengenack TM, Dzeja PP, Poduslo JF (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 7, e32737.
13. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102. (Pubitemid 26332733)
14. Frautschy SA,Yang F, Irrizarry M, Hyman B, Saido TC, Hsiao K, Cole GM (1998) Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152, 307-317. (Pubitemid 28028071)
15. Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 22, 1858-1867. (Pubitemid 35386304)
16. Zhuo JM, Prakasam A, Murray ME, Zhang HY, Baxter MG, Sambamurti K, Nicolle MM (2008) An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. Curr Alzheimer Res 5, 385-391.
17. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2, 2692-2703.
18. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248-254.
19. Robert O, Sabatier J, Desoubzdanne D, Lalande J, Balayssac S, Gilard V, Martino R, Malet-Martino M (2011) pH optimization for a reliable quantification of brain tumor cell and tissue extracts with 1H NMR: Focus on cholinecontaining compounds and taurine. Anal Bioanal Chem 399, 987-999.
20. Barker M, RayensW(2003) Partial least squares for discrimination. J Chemometrics 17, 166-173.
21. Anderssen E, Dyrstad K, Westad F, Martens H (2006) Reducing over-optimism in variable selection by cross-model validation. Chemom Intell Lab Syst 84, 69-74. (Pubitemid 44708396)
22. Eriksson L, Trygg J, Wold S (2008) CV-ANOVA for significance testing of PLS and OPLS models. J Chemometrics 22, 594-600.
23. Steuer R (2006) Review: On the analysis and interpretation of correlations in metabolomic data. Brief Bioinform 7, 151-158. (Pubitemid 44404881)
24. Hansen SH, Andersen ML, Cornett C, Gradinaru R, Grunnet N (2010) A role for taurine in mitochondrial function. J Biomed Sci 17(Suppl 1), S23.
25. Craig A, Cloarec O, Holmes E, Nicholson JK, Lindon JC (2006) Scaling and normalization effects in NMR spectroscopic metabolomic data sets. Anal Chem 78, 2262-2267.
26. Tkac I, Henry PG, Andersen P, Keene CD, LowWC, Gruetter R (2004) Highly resolved in vivo 1H NMR spectroscopy of the mouse brain at 9.4 T. Magn Reson Med 52, 478-484. (Pubitemid 39108958)
27. Zhang X, Liu H, Wu J, Zhang X, Liu M, Wang Y (2009) Metabonomic alterations in hippocampus, temporal and prefrontal cortex with age in rats. Neurochem Int 54, 481-487.
28. Paban V, Fauvelle F, Alescio-Lautier B (2010) Age-related changes in metabolic profiles of rat hippocampus and cortices. Eur J Neurosci 31, 1063-1073.
29. Morgan JJ, Kleven GA, Tulbert CD, Olson J, Horita DA, Ronca AE (2013) Longitudinal 1HMRS of rat forebrain from infancy to adulthood reveals adolescence as a distinctive phase of neurometabolite development. NMR Biomed 26, 683-691.
30. Tkac I, Dubinsky JM,Keene CD, Gruetter R, LowWC (2007) Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J Neurochem 100, 1397-1406.
31. Gomez-Isla T, Price JL, MckeelDW,Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16, 4491-4500. (Pubitemid 26243044)
32. Xu Y, Jack CR, O'Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC (2000) Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54, 1760-1767. (Pubitemid 30428402)
33. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP, Hallikainen M, Vanhanen M, Nissinen A, Helkala EL, Vainio P, Vanninen R, Partanen K, Soininen H (2004) Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 25, 303-310. (Pubitemid 38220965)
34. Gasic GP, Hollmann M (1992) Molecular neurobiology of glutamate receptors. Annu Rev Physiol 54, 507-536.
35. Rigotti DJ, Inglese M, Gonen O (2007) Whole-brain Nacetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders. AJNR Am J Neuroradiol 28, 1843-1849. (Pubitemid 350176510)
36. Ross B, Bluml S (2001) Magnetic resonance spectroscopy of the human brain. Anat Rec 265, 54-84.
37. Isaacks RE, Bender AS, Kim CY, Prieto NM, NorenbergMD (1994) Osmotic regulation of myo-inositol uptake in primary astrocyte cultures. Neurochem Res 19, 331-338. (Pubitemid 24054804)
38. Brewer GJ, Wallimann TW (2000) Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 74, 1968-1978. (Pubitemid 30217652)
39. Bothwell JH, Rae C, Dixon RM, Styles P, Bhakoo KK (2001) Hypo-osmotic swelling-activated release of organic osmolytes in brain slices: Implications for brain oedema in vivo. J Neurochem 77, 1632-1640. (Pubitemid 32574498)
40. Perasso L, Spallarossa P, Gandolfo C, Ruggeri P, BalestrinoM (2013) Therapeutic use of creatine in brain or heart ischemia: Available data and future perspectives. Med Res Rev 33, 336-363.
41. Salek RM, Colebrooke RE, Macintosh R, Lynch PJ, Sweatman BC, Emson PC, Griffin JL (2008) A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene. Neurochem Res 33, 292-300.
42. Chen SQ,Wang PJ, Ten GJ, ZhanW, Li MH, Zang FC (2009) Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 28, 558-566.
43. Forster DM, James MF, Williams SR (2012) Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by H MRS in vitro. NMR Biomed 25, 52-58.
44. von Kienlin M, K̈unnecke B, Metzger F, Steiner G, Richards JG, Ozmen L, Jacobsen H, Loetscher H (2005) Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 18, 32-39. (Pubitemid 40092895)
45. Kim J, Lee S-P, Michaelis ML, Choi I-Y (2009) Detecting progression of Alzheimer's disease pathology in the triple transgenic mouse brain using 1H MRS. Proc Intl Soc Mag Reson Med 17, 3301.
46. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103, 5161-5166.
47. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 45, 583-595. (Pubitemid 38844879)
48. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988) Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451, 205-212.
49. French ED, Vezzani A, Whetsell WO Jr, Schwarcz R (1986) Anti-excitotoxic actions of taurine in the rat hippocampus studied in vivo and in vitro. Adv Exp Med Biol 203, 349-362.
50. Bouckenooghe T, Remacle C, Reusens B (2006) Is taurine a functional nutrient Curr Opin Clin Nutr Metab Care 9, 728-733.
51. Louzada PR, Paula Lima AC, Mendonca-Silva DL, Nöel F, De Mello FG, Ferreira ST (2004) Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: Activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 18, 511-518. (Pubitemid 38326307)
52. Choi JK, Jenkins BG, Carreras I, Kaymakcalan S, Cormier K, KowallNW, DedeogluA(2010) Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol 223, 377-384.
53. Yang D, Xie Z, Stephenson D, Morton D, Hicks CD, Brown TM, Sriram R, O'Neill S, Raunig D, Bocan T (2011)Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible Tau transgenic mice (rTg4510). Neuroimage 54, 2652-2658.
54. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT(1997) APPSwtransgenic mice develop age-relatedAbeta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56, 965-973. (Pubitemid 27386126)
55. Rubin Y, LaPlaca MC, Smith DH, Thibault LE, Lenkinski RE (1995) The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons. Neurosci Lett 198, 209-212.
56. Hanaya R, Kiura Y, Kurisu K, Sakai N, Serikawa T, Sasa M (2008) N-acetyl-L-aspartate activates hippocampal CA3 neurons in rodent slice preparations. Brain Res Bull 75, 663-667. (Pubitemid 351381828)
57. Madhavarao CN, Chinopoulos C, Chandrasekaran K, Namboodiri MA (2003) Characterization of the N-acetylaspartate biosynthetic enzyme from rat brain. J Neurochem 86, 824-835. (Pubitemid 36988795)
58. Danbolt NC (2001) Glutamate uptake. Prog Neurobiol 65, 1-105. (Pubitemid 32479155)
59. Baslow MH (2002) Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system. An analytical review. Neurochem Int 40, 295-300. (Pubitemid 34131602)
60. Pederzolli CD, Rosa AP, de Oliveira AS, Coelho JG, Becker Dda L, Dalazen GR, Moraes TB, Dutra-Filho CS (2010) Neuroprotective role of lipoic acid against acute toxicity of N-acetylaspartic acid. Mol Cell Biochem 344, 231-239.
61. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG (2004) Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 1012, 60-65. (Pubitemid 38648899)
62. Marjanska M, Curran GL, Wengenack TM, Henry PG, Bliss RL, Poduslo JF, Jack CR Jr, Ugurbil K, Garwood M (2005) Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 102, 11906-11910. (Pubitemid 41170823)
63. Xu W, Zhan Y, Huang W, Wang X, Zhang S, Lei H (2010) Reduction of hippocampal N-acetyl aspartate level in aged APP(Swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J Neurosci Res 88, 3155-3160.
64. Mlyńarik V, Cacquevel M, Sun-Reimer L, Janssens S, Cudalbu C, Lei H, Schneider BL, Aebischer P, Gruetter R (2012) Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. J Alzheimers Dis 31, S87-S99.
65. Esteras N, Alqúezar C, Bartoloḿe F, Antequera D, Barrios L, Carro E, Cerd́an S, Mart́n-Requero A (2012) Systematic evaluation of magnetic resonance imaging and spectroscopy techniques for imaging a transgenic model of Alzheimer's disease (A-PP/PS1). J Alzheimers Dis 30, 337-353.
66. Woo DC, Lee SH, Lee DW, Kim SY, Kim GY, Rhim HS, Choi CB, Kim HY, Lee CU, Choe BY (2010) Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APP-PS1 by 1H HR-MAS. Behav Brain Res 211, 125-131.
67. Loos C, Achten E, Santens P (2010) Proton magnetic resonance spectroscopy in Alzheimer's disease, a review. Acta Neurol Belg 110, 291-298.
68. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R (2011) Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 32, 802-810.
69. Fayed N, Modrego PJ, Rojas-Salinas G, Aguilar K (2011) Brain glutamate levels are decreased in Alzheimer's disease: A magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen 26, 450-456.
70. Lei H, Poitry-Yamate C, Preitner F, Thorens B, Gruetter R (2010) Neurochemical profile of the mouse hypothalamus using in vivo 1H MRS at 14.1 T. NMR Biomed 23, 578-583.